Wednesday, 29. March 2017
IDT Biologika receives Life Science Leader’s 2017 CMO Leadership Award in multiple categories
IDT Biologika, a globally integrated contract manufacturer of vaccines and biopharmaceuticals, accepted a CMO Leadership Award for overall quality, reliability, capabilities, expertise, compatibility and development during a ceremony held yesterday in New York City. Sponsored by Life Science Leader magazine, the annual awards recognize the top contract manufacturing organizations (CMOs) serving the pharmaceutical and biopharmaceutical industries.
IDT Biologika Chief Executive Officer Dr. Ralf Pfirmann accepted the 2017 CMO Leadership Award on behalf of the company. “With our competence and wide range of capabilities in industrial development and manufacture, IDT is the most helpful partner for all organizations working on new solutions with the mission of bringing new vaccines or biological drugs to patients,” said Dr. Pfirmann. “Our increasing worldwide recognition is based on our dedication to serving these needs. The success of our customers is highlighted by the multiple categories of the CMO award in which we are decorated this year.”
Winners were evaluated based on real-world experiential data and feedback from decision makers who work with contract manufacturing suppliers. IDT was judged by its customers as a top performer among more than 80 CMOs. The company achieved this high honor in all six categories across 30 performance metrics considered important to the selection of a CMO and based on customers’ direct experience working with IDT on an outsourced project within the last 18 months. Life Science Leader teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers.
The award adds to IDT’s distinguished reputation in the contract services business and celebrates the company’s ongoing commitment to manufacturing excellence. Today, IDT offers a wide range of services during all phases of vaccine and biopharmaceutical development – from early research and process development through clinical and mass commercial manufacturing.
IDT continues to increase its global footprint and has expanded its infrastructure in Dessau, Germany and Rockville, Maryland. The company is particularly focused on developing new medical solutions for the U.S. market and recently become a prime contractor for the Biomedical Advanced Research and Development Authority (BARDA), an office of the U.S. Department of Health and Human Services. For more information, visit IDT Biologika on the web at www.idt-biologika.com.